Anti-androgenic mechanism of a new compound
Anti-androgenic mechanism of a new compound
批准号:
6550419
负责人:
CHARLES C-Y SHIH
金额:
$9.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-30 至 2003-09-29
中文摘要
描述(申请人提供):雄激素阻断治疗可以缓解晚期局部前列腺癌的症状;然而,一旦肿瘤演变成激素抵抗阶段,就没有有效的治疗方法。抗雄激素(用于雄激素阻断治疗)或其他“非常规”激动剂对AR的持续激活可能导致去雄激素后患者前列腺癌的进展。从概念上讲,不仅睾丸雄激素,而且其他激动剂都能阻断AR功能的药物在雄激素敏感和不敏感阶段都能更好地降低前列腺癌的发病率。我们最近发现二阿魏酰甲烷的衍生物(化合物4)抑制了双氢睾酮诱导的人前列腺癌细胞雄激素受体的反式激活。该制剂还能抑制双氢睾酮诱导的LNCaP细胞生长。此外,化合物4还能有效抑制广泛使用的抗雄激素羟基氟他胺刺激的LNCaP细胞生长和AR反式激活。根据这些初步数据,我们在这项研究中建议:
(1)进一步检测化合物4是否取消醋酸环丙孕酮、雌二醇、脱氢表雄酮和雄烯二醇所引起的AR作用。这些抗雄激素或类固醇激素已被证明具有残留的AR激动剂活性,并可能在雄激素阻断治疗后的患者中大量存在。
(2)探讨化合物4拮抗AR的作用机制。化合物4可能在多个步骤中干扰AR途径。在这项初步研究中,我们将研究最可能的机制--化合物4是通过下调AR表达来阻断雄激素诱导的生物反应,还是通过竞争性地抑制睾丸雄激素与受体的结合。
新型抗雄激素药物的发现对预防雄激素依赖性和非雄激素依赖型前列腺癌的临床应用有直接影响。
英文摘要
DESCRIPTION (provided by applicant): Androgen blockage therapy may relieve the symptom of an advanced, localized prostate tumor; however, once the tumor evolves into a hormone-refractory stage, there is no effective treatment. A continuous activation of AR by antiandrogens (used in androgen blockage therapy) or other "nonconventional" agonists may contribute to prostate cancer progression in patients after androgen deprivation. Conceptually, pharmacological agents blocking AR function evoked by not only testicular androgens but also other agonists would have a superior capacity to decrease prostate cancer incidence at both the androgen-sensitive and -insensitive stages. We recently found that a derivative of diferuloylmethane (Compound 4) inhibited dihydrotestosterone-induced androgen receptor transactivation in human prostate cancer cells. This agent also suppressed dihydrotestosterone-induced LNCaP cell growth. Furthermore, Compound 4 was effective in decreasing LNCaP cell growth and AR transactivation stimulated by hydroxyflutamide, a widely used antiandrogen. Based upon these preliminary data, we propose in this study to:
(1) Further test whether Compound 4 abolishes AR function elicited by cyproterone acetate, estradiol, dehydroepiandrosterone, and androstenediol. These antiandrogen or steroid hormones have been documented to have residual AR agonist activity and may exist in significant amounts in patients after androgen blockage therapy.
(2) Explore the mechanisms of action of Compound 4 to antagonize the AR. Compound 4 may disrupt the AR pathway at multiple steps. In this preliminary study, we will examine the most likely mechanisms- whether Compound 4 blocks androgen-induced biological response via a down-regulation of AR expression, or via a competitive suppression of testicular androgens' binding to the receptor.
The discovery of a novel antiandrogen capable of preventing both androgen-dependent and androgen-independent prostate cancer may have a direct impact in clinical application.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of an Oral Therapeutic Drug for Spinal and Bulbar Muscular Atrophy
-
批准号:8252177
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:CHARLES C-Y SHIH
-
依托单位:
Development of an Oral Therapeutic Drug for Spinal and Bulbar Muscular Atrophy
-
批准号:8041399
-
项目类别:
-
资助金额:$86.22万
-
财政年份:2011
-
负责人:CHARLES C-Y SHIH
-
依托单位:
Development of an Oral Therapeutic Drug for Spinal and Bulbar Muscular Atrophy
-
批准号:8723309
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:CHARLES C-Y SHIH
-
依托单位:
A New Topical Antiandrogen Benefits Acne Treatment
-
批准号:7274871
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2004
-
负责人:CHARLES C-Y SHIH
-
依托单位:
A New Topical Antiandrogen Benefits Acne Treatment
-
批准号:6831937
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2004
-
负责人:CHARLES C-Y SHIH
-
依托单位:
A New Topical Antiandrogen Benefits Acne Treatment
-
批准号:7155625
-
项目类别:
-
资助金额:$44.6万
-
财政年份:2004
-
负责人:CHARLES C-Y SHIH
-
依托单位:
Cell-Based High Throughput Screening for Anti-Androgens
-
批准号:6484915
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2002
-
负责人:CHARLES C-Y SHIH
-
依托单位:
ANTI-ANDROGEN RECEPTOR MABS FOR HUMAN PROSTATE CANCER
-
批准号:3493269
-
项目类别:
-
资助金额:$5.0万
-
财政年份:1993
-
负责人:CHARLES C-Y SHIH
-
依托单位:
海外基金